170 related articles for article (PubMed ID: 32340536)
21. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review.
Zhao X; Feng Z; Wang G; Pang H; Wang M
Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011
[TBL] [Abstract][Full Text] [Related]
22. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
23. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Won B; Mambetsariev I; Salgia R
BMC Cancer; 2016 Aug; 16():568. PubMed ID: 27480287
[TBL] [Abstract][Full Text] [Related]
24. [Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].
Satouchi M; Nishio M; Hida T; Nakagawa K
Gan To Kagaku Ryoho; 2018 Feb; 45(2):257-264. PubMed ID: 29483416
[TBL] [Abstract][Full Text] [Related]
25. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Landi L; Cappuzzo F
Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
[TBL] [Abstract][Full Text] [Related]
26. Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study.
Kaneda H; Kizaki M; Ochi M; Shiraiwa N; Akatsu S
Sci Rep; 2020 Oct; 10(1):16773. PubMed ID: 33033286
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
[TBL] [Abstract][Full Text] [Related]
28. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.
Otoukesh S; Sanchez T; Mirshahidi S; Wallace D; Mirshahidi H
Cancer Treat Res Commun; 2019; 20():100149. PubMed ID: 31075537
[TBL] [Abstract][Full Text] [Related]
29. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
[TBL] [Abstract][Full Text] [Related]
30. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
31. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
32. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
34. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer.
Cooper MR; Chim H; Chan H; Durand C
Ann Pharmacother; 2015 Jan; 49(1):107-12. PubMed ID: 25258420
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
36. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
De Pas T; Pala L; Catania C; Conforti F
Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
[TBL] [Abstract][Full Text] [Related]
37. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
[TBL] [Abstract][Full Text] [Related]
38. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.
Straughan DM; Azoury SC; Shukla V
Curr Drug Targets; 2016; 17(6):739-45. PubMed ID: 26073862
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
